115 Munson Street
New Haven, CT 06511
Adela is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a blood test.
The DNA methylome is a rich source of information about human disease. Adela’s genome-wide methylation enrichment technology uniquely captures information efficiently from the entire methylome. Adela’s technology distinguishes the most-highly informative (methylated) regions of the genome from non-informative regions and preferentially targets those regions for sequencing.